Cost-effectiveness of three different vaccination strategies against measles in Zambian children

Vaccine

Volumn 22, Issue 3-4, 2004, Pages 475-484

  Dayan, Gustavo H ^a   Cairns, Lisa ^a   Sangrujee, Nalinee ^a   Mtonga, Anne ^b   Nguyen, Van ^c   Strebel, Peter ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b Central Board of Health   (Zambia)

^c Gouvernement du Quebec   (Canada)

Author keywords

Analysis; Cost; Measles

Indexed keywords

MEASLES VACCINE;

ANALYTIC METHOD; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; HEALTH SERVICE; HUMAN; IMMUNIZATION; INFANT; MEASLES; MEASLES VACCINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SIMULATION; SINGLE DRUG DOSE; STATISTICAL PARAMETERS; ZAMBIA;

EID: 0344234354     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.07.007     Document Type: Article

References (53)

1. Murray CJL, Lopez AD, Mathers CD, Stein C. The global burden of disease 2000 project: aims, methods and data sources. World Health Organization; 2001.
2. World Health Organization. Global measles. Mortality reduction and regional elimination. Strategic plan 2001-2005. World Health Organization; 2000.
3. World Health Organization. Principles for measles control and elimination. World Health Organization; 2001.
4. http://www.unicef.org/statis/country_1page192.html.
5. Ministry of Health, Zambia. Sub-national immunization days, 1999. Report. Government of Zambia, WHO, UNICEF; 1999.
6. United Nations Children's Fund. Emergency Measles Campaign Southern Province, Zambia. Preliminary Progress Report. UNICEF; 25-29 November 2002.
7. World Health Organization. Vaccine-preventable diseases: monitoring system. 2001 global summary. Geneva: Department of Vaccines and Biologicals; 2001.
8. Cutts F.T., Grabowsky M., Markowitz L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals. 23:1995;95-106.
9. Krugman S., Giles J.P., Jacobs A.M., Friedman H. Studies with live attenuated measles-virus vaccine. Am. J. Dis. Child. 103:1962;353-363.
10. Krugman S., Giles J.P., Jacobs A.M., Friedman H. Studies with a further attenuated live measles-virus vaccine. Pediatrics. 31:1963;919-928.
11. Krugman S., Giles J.P., Friedman H., Stone S. Studies on immunity to measles. J. Pediatr. 66:1965;471-488.
12. Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev. Infect. Dis. 5:1983;477-481.
13. Watson J.C., Pearson J.A., Markowitz L.E., Baughman A.L., Erdman D.D., Bellini W.J.et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics. 97:1996;613-618.
14. Wittler R.R., Veit B.C., Mcintyre S., Schydlower M. Measles revaccination response in a school-age population. Pediatrics. 88:1991;1024-1030.
15. Poland G.A., Jacobson R.M., Thampy A.M.et al. Measles reimmunization in children seronegative after initial immunization. JAMA. 277:1997;1156-1158.
16. Ministry of Health, Zambia. Sustaining the benefits of immunization within Zambian health reform, 1999.
17. Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: Saunders; 1999.
18. Ministry of Health, Zambia. Survey of knowledge, attitudes and practices carried out in 1999 after a measles vaccination campaign in four urban districts of Zambia. Zambia; 1999.
19. Chen R.T., Moses J.M., Markowitz L.E., Orenstein W.A. Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine. 9:1991;297-299.
20. Ministry of Health Zambia. Child Health Statistics 1999, all quarters.
21. Ministry of Health, Zambia, Central Board of Health, Zambia. Sub-national immunization days, 2000.
22. Centers for Disease Control and Prevention. Measles incidence before and after supplementary vaccination activities, Lusaka, Zambia, 1996-2000. MMWR 2000;50(24):513-6.
23. World Health Organization, World Health Assembly. Executive summary. Geneva; 1989 (Resolution WHA 42.32).
24. United Nations Children's Fund. Plan of action for implementing the world declaration on the survival, protection and development of children in the 1990s. New York: UNICEF; 1990.
25. Witte J.J., Axnick N.W. The benefits from 10 years of measles immunization in the United States. Public Health Rep. 90:1975;205-207.
26. Willems J.S., Sanders C.R. Cost-effectiveness and cost-benefit analyses of vaccines. J. Infect. Dis. 144:1981;486-493.
27. Koplan JP, White CC. An update on the benefits and costs of measles and rubella immunization. In: Grunberg EM, Lewis C, Goldston, editors. Immunizing against mental disorders: progress in the conquest of measles and rubella. Oxford: Oxford University Press; 1985.
28. White C.C., Koplan J.P., Orenstein W.A. Benefits, risks and costs of immunization for measles, mumps and rubella. Am. J. Public Health. 75:1985;739-744.
29. Vargas Fores L.A., Nunez Gomiciaga E. El análisis de costo-beneficio en un programa nacional de inmunización contra el sarampión en México. Salud. Pública. de México. 26:1984;373-380.
30. Centres for Disease Control and Prevention. Measles Outbreak, Romania. MMWR 1997;49:1159-63.
31. Puvimanasinghe JPA, Arambepola CK, Abeysinghe NMA, Rajapaksa LC, Kulatilaka TA. Measles outbreak in Sri Lanka. JID, in press.
32. Health and Welfare Canada. Measles in Canada - 1988, and 1989. Canada diseases weekly report 1990;16(1):1-6.
33. Centers for Disease Control and Prevention. Measles - United States. MMWR1988;38:601-5.
34. Tulchinsky T.H., Ginsberg G.M., Abed Y., Angeles M.T., Akukwe C., Bonn J. Measles control in developing and developed countries: the case for a two-dose policy. WHO Bull. 71(1):1993;93-103.
35. Committee on Infectious Diseases, American Academy of Pediatrics. Measles: reassessment of the current immunization policy. Pediatrics 1989;84:1110-3.
36. Bottiger M., Christenson B., Romanus V. Swedish experience of two-dose vaccination programme aiming at eliminating measles, mumps and rubella. BMJ. 295:1987;1264-1267.
37. Chauvin P., Valleron A.J. Dix années de surveillance de la rougeole en France à travers un reseau de médecins sentinelles. Cahiers Santé 4:1994;191-194.
38. Verbrugge H.P. The national immunization program of The Netherlands. Pediatrics. 85:1990;S1060-S1063.
39. Ginsberg G.M., Tulchinsky T.H. Cost and benefits of a second measles inoculation of children in Israel. J. Epidemiol. Community Health. 44(4):1990;274-280.
40. Ministry of Health Zambia. Proposal on Accelerated Measles Control in Zambia, 2002.
41. Global Programme for Vaccines of the World Health Organization. Role of mass campaigns in global measles control. Lancet 1994;344:174.
42. Zuber P.L.F., Ghislaine Conombo K.S., Démbelé Traoré A., Milogo J.D., Ouattara A., Ouéedrago I.B.et al. Mass measles vaccination in urban Burkina Faso 1998. Bull. World Health Organ. 79:2001;296-300.
43. Durrheim D.N., Ogunbanjo G.A. Measles elimination - is it achievable. Lessons from an immunisation coverage survey. S. Afr. Med. J. 90(2):2000;130-135.
44. Pelletier L., Chung P., Duclos P., Manga P., Scott J. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine. 16:1998;986-996.
45. Ponninghaus J.M. The cost/benefit of measles immunization: a study from Southern Zambia. J. Trop. Med. Hyg. 83(4):1980;141-149.
46. Krugman S, Katz SL. Infectious disease of children. St. Louis: CV Mosby; 1981. p. 149-55.
47. Modlin J.F., Jabbour J.T., White J.J.et al. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics. 59:1977;505-512.
48. Murray CJL, Lopez AD, Mathers CD, Stein C. The global Burden of Disease 2000 project: aims, methods and data sources. http://www.who.int/whosis/burden/ papers/discussion%20paper%20revised.doc .
49. Aaby P., Buckh J., Lisse I.M., da Silva M.C. Decline in measles mortality: nutrition, age at infection, or exposure? BMJ. 296:1988;1225-1228.
50. Dollimore N., Cutts F., Binka F.N., Ross D.A., Morris S.S., Smith P.G. Measles incidence, case fatality, and delayed mortality in children with or without Vitamin A supplementation in rural Ghana. Am. J. Epidemiol. 146:1997;646-654.
51. Stein CE, Birmingham M, Kurian M, Duclos P, Strebel P. The global burden of measles in the year 2000 - a model that uses country-specific indicators. JID 2003;187:S8-S14.
52. Cutts F. Measles control in young infants: where do we go from here? Lancet. 341:1993;290-292.
53. Samb B., Aaby P., Whittle H., Seck A.M.C., Simondon F. Decline in measles case fatality ratio after the introduction of measles immunization in rural Senegal. Am. J. Epidemiol. 145:1997;51-57.